| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 18 Sep 2026 |
8-K: Other Events
On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial. |
| 02 Sep 2026 |
Form 4: Lundquist Kevin Michael, Chief Financial Officer
Granted 500,000 Employee Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 3: Lundquist Kevin Michael, Chief Financial Officer
No securities owned |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (this “Agreement”) effective as of September 1, 2026 (“Effective Date”) is entered into between Outlook Therapeutics, Inc., a Delaware corporation with its principal place of business at 111 S. Wood, A... |
| 19 Aug 2026 | SCHEDULE 13G |
| 18 Aug 2026 | 10-Q |
| 17 Aug 2026 | NT 10-Q |
| 14 Aug 2026 | SCHEDULE 13D/A |
| 14 Aug 2026 |
Form 4: Sukhtian Ghiath M., Director and 1 other
Bought 2,525,252 shares ($2.5M) · Acquired 2,525,252 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 |
Form 4: Jahr Robert Charles, Director
Bought 151,515 shares · Acquired 151,515 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 |
Form 4: Kenyon Lawrence A, Director
Bought 101,010 shares · Acquired 101,010 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 |
8-K: Other Events
Warrants to Purchase up to 55,555,556 Shares of Common Stock |
| 14 Aug 2026 | 424B5 |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ |
| 12 Aug 2026 | 424B5 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
You should consider carefully the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of operations, and prospects could be adversely affected. The risks describ... |
| 29 Jul 2026 |
Form 4: Sukhtian Faisal Ghiath, Director
Bought 95,398 shares ($100K) |
Loading...